Welcome to our dedicated page for Exicure news (Ticker: XCUR), a resource for investors and traders seeking the latest updates and insights on Exicure stock.
Exicure, Inc. (Nasdaq: XCUR) is a clinical-stage biotechnology company developing therapies for hematologic diseases, with a lead focus on the small molecule CXCR4 antagonist burixafor (GPC-100). The Exicure news feed highlights how the company advances this program across multiple indications and how its financial and corporate decisions affect the XCUR stock story.
Readers can follow updates on Exicure’s clinical trials, including an open-label, multicenter Phase 2 study of burixafor in combination with propranolol and G-CSF in patients with multiple myeloma undergoing autologous hematopoietic cell or stem cell transplantation. Company announcements describe topline and interim results, rates of successful CD34+ cell mobilization, engraftment outcomes for participants who proceed to transplant, and safety observations for the burixafor-based regimen.
News items also cover pipeline expansion plans, where Exicure discusses potential use of burixafor in sickle cell disease, rare diseases requiring autologous transplant, cell and gene therapy settings, and as a potential chemosensitizing agent in acute myeloid leukemia (AML). These releases outline how mobilizing hematopoietic or malignant cells from the bone marrow niche into peripheral blood could support transplant procedures or enhance chemotherapy effectiveness.
In addition, the XCUR news stream includes financial results and going concern disclosures, detailing quarterly cash balances, research and development and general and administrative expenses, and management’s assessment that additional financing is needed to fund operations and strategic alternatives. Corporate governance and listing-related developments, such as Nasdaq compliance notices, annual meeting information, and board composition changes, are also reported.
Investors and followers of Exicure can use this page to monitor clinical data presentations, strategic updates related to the acquisition of GPCR Therapeutics USA Inc., and regulatory or capital markets filings that shape the company’s hematology-focused trajectory. Bookmark this feed to review new press releases and regulatory-linked news as they are published.
Exicure (Nasdaq: XCUR) has completed the last patient visit in its Phase 2 clinical trial evaluating GPC-100 (burixafor) for stem cell mobilization in multiple myeloma patients. The study assesses GPC-100's ability to improve CD34+ hematopoietic stem cell mobilization for autologous stem cell transplant (ASCT).
Key highlights include GPC-100's differentiated rapid mobilization time of just 45 minutes before collection, compared to traditional overnight procedures. The company expects topline results in Q4 2025. Beyond multiple myeloma, Exicure plans a Phase 1 study in acute myeloid leukemia and is exploring potential collaborations for cell and gene therapy applications.
Exicure (Nasdaq: XCUR) reported Q1 2025 financial results, posting a net income of $3.0 million compared to a net loss of $0.8 million in Q1 2024. The company's cash position stood at $10.4 million as of March 31, 2025, down from $12.5 million at the end of 2024.
The quarter's performance was primarily driven by a $6 million gain from early lease termination in Chicago, offset by increased operating expenses following the GPCR USA acquisition. R&D expenses increased to $0.8 million, while G&A expenses rose to $2.2 million.
Notably, management expressed significant concern about the company's financial sustainability, stating that current cash reserves are insufficient to fund ongoing operations and substantial additional financing is urgently needed.
Exicure (NASDAQ: XCUR) has received a non-compliance notice from Nasdaq on May 21, 2025, due to failing to file its Q1 2025 Form 10-Q by the May 20, 2025 deadline. The company now has 60 calendar days to submit a compliance plan to Nasdaq. If accepted, Exicure could receive up to 180 calendar days (until November 17, 2025) to regain compliance with Nasdaq Listing Rule 5250(c)(1). The company states it is working to complete and file the Form 10-Q as soon as possible.
Exicure (NASDAQ: XCUR) has completed patient enrollment in its Phase 2 clinical trial evaluating GPC-100 (burixafor) in combination with propranolol and G-CSF for stem cell mobilization in multiple myeloma patients undergoing autologous stem cell transplant. The study aims to assess if GPC-100, a CXCR4 antagonist, can enhance CD34+ hematopoietic stem cell mobilization from bone marrow to peripheral blood for collection via leukapheresis. Topline results are expected in Fall 2025.
Beyond multiple myeloma, Exicure is planning a Phase 1 chemosensitization study in relapsed/refractory acute myeloid leukemia (AML) patients. The company is also exploring GPC-100's potential in other areas requiring stem cell mobilization, including sickle cell disease, rare diseases needing autologous transplant, and cell and gene therapy applications.
Exicure (XCUR) has reached a significant milestone in its Phase 2 clinical trial of GPC-100 (burixafor), having dosed 19 patients to evaluate stem cell mobilization in multiple myeloma patients undergoing autologous stem cell transplant. The open-label, multi-center trial assesses GPC-100 and propranolol combined with G-CSF.
Interim analysis data from 10 patients presented at the 2024 ASH Annual Meeting showed promising results, with 100% of patients achieving successful CD34+ stem cell mobilization, including those previously treated with daratumumab. A key advantage of GPC-100 is its same-day administration and leukapheresis capability, offering faster treatment compared to FDA-approved alternatives like plerixafor and motixafortide.
The study reported median neutrophil and platelet engraftment times of 11 and 14 days respectively, aligning with standard care expectations. Patient recruitment is scheduled to conclude by the end of April.
Exicure (XCUR) has announced plans for a new clinical trial of its lead asset GPC-100 (burixafor) in Acute Myeloid Leukemia (AML). The CXCR4 inhibitor has shown promise when combined with modern AML treatments. A previous Phase 1 study with 15 relapsed/refractory AML patients evaluated GPC-100's safety and preliminary efficacy in combination with fludarabine and cytarabine.
Recent preclinical data presented at the 2024 ASH Annual Meeting demonstrated improved chemotherapy response through dual inhibition of CXCR4 with GPC-100 and beta-2 adrenergic receptor blockade. The company has secured patents for this approach in multiple countries.
GPC-100 is currently in a Phase 2 trial for multiple myeloma patients undergoing autologous stem cell transplant, with results expected in Q4 2025. Exicure is also exploring potential expansions into sickle cell disease, pediatric oncology, and cell and gene therapy applications.
Exicure (XCUR) reported its full year 2024 financial results, showing a mixed financial picture. The company's cash position improved to $12.5 million as of December 31, 2024, compared to $0.8 million in 2023. However, management expressed substantial doubt about continuing operations, stating additional financing is needed.
The company reported zero R&D expenses in 2024, down from $1.4 million in 2023, reflecting the complete suspension of all research activities. G&A expenses decreased to $5.4 million from $11.7 million in 2023. The net loss improved to $9.7 million in 2024 from $16.9 million in 2023.
Following its September 2022 strategic shift, which included workforce reduction and suspension of all R&D activities, Exicure continues exploring strategic alternatives to maximize stockholder value, including potential partnerships with companies interested in joining a publicly-traded organization.
Exicure (Nasdaq: XCUR) has secured Patent No. 2018388302 from the Australian Patent Office for its 'GPCR Heteromer Inhibitors and Uses Thereof.' The patent covers a novel combination approach to cancer treatment targeting CXCR4 and GPCRx.
The patent supports Exicure's ongoing Phase 2 clinical trial (NCT05561751) evaluating the combination of GPC-100 and propranolol in multiple myeloma patients. The method aims to enhance hematopoietic stem cell mobilization through co-targeting CXCR4 and ADRB2, potentially improving the efficacy of CXCR4 inhibitors like GPC-100.
The patent has already been granted in the United States, Japan, and Taiwan, with applications pending in other jurisdictions.
Exicure (XCUR) has announced a significant strategic move by acquiring GPCR Therapeutics USA Inc., a California-based and former wholly-owned subsidiary of Korean GPCR Therapeutics Inc. The acquisition was executed through a Share Purchase Agreement on January 19, 2025.
Concurrent with the acquisition, Exicure and GPCR entered into a License and Collaboration Agreement focused on developing and commercializing GPCR's technologies. Under this agreement, Exicure commits to milestone payments tied to clinical trials, marketing authorizations, and net sales achievements. The agreement includes a minimum 10% royalty payment on net sales, with specific milestones such as a $30 million payment when first annual net sales exceed $400 million.
Exicure (NASDAQ: XCUR) has announced a significant strategic move through a Share Purchase Agreement with GPCR Therapeutics Inc., a Korean The agreement, executed on January 19, 2025, involves Exicure's acquisition of all issued and outstanding equity securities of GPCR Therapeutics USA Inc., a California-based previously wholly owned by GPCR.
Concurrent with this acquisition, both companies established a License and Collaboration Agreement (L&C Agreement) focused on developing and commercializing GPCR's technological intellectual properties and patents. Under the terms of the L&C Agreement, Exicure commits to:
- Making milestone payments tied to clinical trials progress
- Marketing authorization achievements
- Net sales performance
- Paying a recurring royalty of at least 10% on net sales